The Cost-Effectiveness of Brentuximab Vedotin As Consolidation Treatment After Autologous Stem-Cell Transplantation in Patients With Hodgkin Lymphoma and Increased Risk of Relapse

Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.223
https://www.valueinhealthjournal.com/article/S1098-3015(17)30557-0/fulltext
Section Title : Disease-Specific Studies
Section Order : 203
First Page : A437
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30557-0&doi=10.1016/j.jval.2017.08.223
HEOR Topics :
Tags :
Regions :